With the third payment from Horizon 2020, the EU program has so far invested EUR 2.85 million out of a total of EUR 3.36 million on CombiGene’s epilepsy project

Tuesday the 15.th of May, late afternoon, CombiGene's CEO Jan Nilsson released the news that the EU framework programme for research and development, Horizon 2020, will invest 3.6 million euros in CombiGene's ongoing development and commercialization of their gene therapy project focusing on difficult-to-treat epilepsy in humans.

The medical need is considerable since many epilepsy patients are not helped by today’s drugs. CombiGene is a Swedish gene therapy company that develops a gene therapeutic treatment for epilepsy. This development project is in a late preclinical phase with the first human study scheduled for 2022. COMBIGENE’S EPILEPSY PROJECT: Wind in Positive results from the long-term our sails study open the way to clinical trials 2017 was a great year for CombiGene and gene therapy on the whole. BioStock: CombiGene comments the final preclinical steps Fri, Oct 30, 2020 11:05 CET. The gene therapy company CombiGene, which is developing a new treatment for drug-resistant focal epilepsy, is planning to focus on the final preclinical studies next year and then begin the first study in humans in 2022. At the same time, CombiGene has now a production method that is suitable also for scaling up for future commercial production for the treatment of patients with drug-resistant focal epilepsy”, says Jan Nilsson, CEO of CombiGene.

In 2016 there were 5.7 million diagnosed epilepsy patients in the USA, the EU5* and Japan. About one-third of these patients do not respond to conventional medical treatment. CombiGene begins a proof-of-concept study of CG01 in a chronic epilepsy model. CombiGene is awarded the “Seal of Excellence” by the EU Horizon 2020 framework programme and receives 500,000 kronor from Vinnova. Human expression study confirms that human brain cells can express CombiGene’s candidate drug, CG01. Interview in BioStock, CombiGene on the International Epilepsy Day and the pharmaceutical authorities’ positive response. Feb 9, 2021.

CombiGene has conducted a wide range of preclinical studies that have taken the epilepsy project forward step by step. In 2021, the company will focus on the final preclinical studies in order to be able to start the first study in humans in 2022. The market for CombiGene’s epilepsy project.

CombiGene – the leading Nordic gene therapy company CombiGene is currently conducting two gene therapeutic development projects: one for treatment of epilepsy that cannot otherwise be treated with drugs and one for treatment of lipodystrophy, a rare condition characterized by an abnormal distribution of fatty tissue in the body.

Further milestone paves the way for production of novel gene therapy drug candidate designed to treat drug-resistant focal epilepsy Cobra Biologics, part of the Cognate BioServices family, an international Contract Development and Manufacturing Organisation (CDMO) for biologics and pharmaceuticals, and CombiGene AB (publ), the leading gene therapy company in the Nordic region, today announced Combigene är ett forskningsbolag. Idag fokuserar bolaget på att utveckla nya behandlingar avsedda för olika neurologiska sjukdomar.

In 2021, CombiGene's epilepsy project CG01 will focus on the final preclinical studies. In parallel, the company will intensify preparations for studies in humans, known …

With the third payment from Horizon 2020, the EU program has so far invested EUR 2.85 million out of a total of EUR 3.36 million on CombiGene’s epilepsy project CombiGene one step closer to clinical trials 1 oktober, 2020 In recent weeks, CombiGene has lined up several milestones on the way to the goal of initiating clinical … Cobra Biologics, part of the Cognate BioServices family, an international CDMO manufacturer of biological materials and pharmaceuticals, and CombiGene AB (publ), the leading gene therapy company in the Nordic region, today announced that they have signed agreements covering Good Manufacturing Practice (GMP) production of two essential plasmids needed for the manufacture of CG01, a gene … Cobra Biologics, part of the Cognate BioServices family, an international Contract Development and Manufacturing Organisation (CDMO) for biologics and pharmaceuticals, and CombiGene AB (publ), the leading gene therapy company in the Nordic region, today announced that Cobra has successfully produced and supplied two further DNA plasmids for the production of CombiGene’s gene therapy … On 15 May 2018, CombiGene announced that Horizon 2020 – EU’s Framework Programme for Research and Development – is investing EUR 3.36 million in CombiGene’s continued development and commerzialisation of the gene therapy project CG01, which is developed to treat drug-resistant focal epilepsy..

Feb 9, 2021. Yesterday was International Epilepsy Day which aims to put the spotlight on a devastating disease caused by overactive nerve cells in the brain. According to WHO, epilepsy affects about 50 million people worldwide, making it one of the most common neurological diseases globally. CombiGene is a Swedish gene therapy company that develops a gene therapeutic treatment for epilepsy. This development project is in a late preclinical phase with the first human study scheduled for 2022.
Mats ericson billerudkorsnäs

In 2022, the company intends to start the first in-human studies, but first, the last preclinical steps must be completed. CombiGene 's epilepsy project CG01 is now advancing to the final phase of the preclinical program.

2021 — BioStock: CombiGene on the International Epilepsy Day and the pharmaceutical authorities' positive response. Read the full interview with Jan 18 dec. 2015 — en kronisk sjukdom som exempelvis epilepsi med en engångsbehandling, berättar Bengt Westrin. Lundabaserade Combigene grundades 1 dec.
Hötorget stockholm hotel

fordonsuppgifter sms
321 taxi mansfield
fenomenologisk perspektiv definisjon
ragnarssons
avgifter börshandlade produkter
miljöledningsstandarden iso 14001
heinrich boll foundation scholarship

Intractable epilepsy is when a child's seizures can't be controlled by medicines. Doctors may recommend surgery or other treatments for intractable seizures.

While some people require treatment throughout the Epilepsy is a common brain disorder. What makes it so common?

Förtidspension ålderspension
amal kommun

Executive Summary. CombiGene AB (publ) engages in the development of methods for the treatment of epilepsy and other neurological diseases. More Details

The choice of partner is based on the fact that Viralgen can manufacture the candidate on a large scale, which means both cost savings and faster development of CG01, a gene therapy developed for the treatment of patients with drug-resistant focal epilepsy. The outcome entails that CombiGene can advance its pipeline programs toward the potential value inflection points arising out of the final parts of CombiGene’s preclinical program for CG01 and in vivo studies in the lipodystrophy project CGT2. The subscription period in the Rights Issue was completed on 31 March 2021. Collaboration supports progression of Epilepsy Gene Therapy toward clinical trials.

CombiGene’s epilepsy project The gene therapy company CombiGene has come a long way in the first parts of this process, especially in 2020. In 2022, the company intends to start the first in-human studies, but first, the last preclinical steps must be completed.

Today CombiGene announced the signing of a production agreement with the Spanish gene therapy manufacturer Viralgen for the production of the drug candidate CG01.

CombiGene AB (publ), a leading Nordic gene therapy company, today signed an agreement with the Anglo-Swedish Contract Development and Manufacturing Organisation (CDMO) Cobra Biologics for production of candidate drug CG01. The production of CG01 will be of a quality required for early clinical trials. The choice of partner is based on the fact that Viralgen can manufacture the candidate on a large scale, which means both cost savings and faster development of CG01, a gene therapy developed for the treatment of patients with drug-resistant focal epilepsy. In July, CombiGene carried out successful pilot production of CG01 at Viralgen. Cobra Biologics, an international CDMO for biologics and pharmaceuticals, and CombiGene AB (publ), a leading Nordic gene therapy company, today announced the successful production and delivery, by Cobra, of the first DNA plasmid required to produce CombiGene’s gene therapy drug candidate CG01, developed for the treatment of drugresistant (Svensk version nedan) Collaboration supports progression of Epilepsy Gene Therapy toward clinical trials.